Figure 7.

Cumulative survival of patients with immunohistochemical other-type tumors. Patients with tumors showing coexpression of MUC5AC and MUC6 showed significantly better survival than those with tumors negative for expression of both MUC5AC and MUC6 (p = 0.048).